Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins also elevate high-density lipoprotein cholesterol (HDL-C) in a dose-dependent manner by up to + 10% [32].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [32]
In the citing paper
“Moreover, the long-term safety of the regular consumption of these products has not been fully documented and safety issues due to the possible presence of contaminants in some preparations have been raised.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Different commercial preparations of RYR have different concentrations of monacolins, and lower TC and LDL-C levels to variable extents, but the consumer is not able to make that distinction [144,185].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Hypocholesterolaemic effects of RYR are related to a statin-like mechanism-inhibition of hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase-of monacolins, which represent the bioactive ingredient.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“In a meta-analysis 291 of several intervention studies in dyslipidaemic patients, elevations in HDL-C varied with dose among the respective statins; such elevations were typically in the range of 5-10%.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [291]
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Diabetes and atherosclerosis: An epidemiologic view
Pyörälä, K., Laakso, M., & Uusitupa, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 919
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Self-citationPedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., McGarry, T., Bettis, R., Melani, L., Lipka, L. J., LeBeaut, A. P., Suresh, R., Sun, S., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 558
Cited by
Items 201–260 of 260
Fancher, A. J., López‐Candales, A., & Sawalha, K. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.216 · Cited by 1
“27 The effect of statins on triglycerides has also been noted to vary by statin type and the dose.”
Tsai, Y., Mudiyanselage, S. P. K., Tsai, Y., Maithreepala, S. D., Liu, W.-C., Ko, N., Yeh, J., Wei-Lin, C., Hsu, P.-I., Chou, C., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02208-x · Cited by 1
“Previous studies also showed that statins could improve HDL-C [19, 20].”
Sawhney, A. G., & Rothkopf, M. M. (2014) · CRC Press eBooks · doi:10.1201/b17616-7 · Cited by 2
Statins and COVID-19 (Mechanism of Action, Effect on Prognosis)
Lewek, J., Surma, S., & Banach, M. (2022) · Contemporary cardiology · doi:10.1007/978-3-031-15478-2_17 · Cited by 2
Choe, J., Lee, S. H., Ahn, J., Lee, H., Oh, J., Choi, J., Lee, H., Cha, K., & Park, J. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186099 · Cited by 3
“As shown in our study, the HDL-C levels increased in a dose-dependent manner with rosuvastatin therapy [24].”
ResultZhang, J., Li, Y., & Shi, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1502025 · Cited by 1
Kudinov, V. A., Zakharova, T. S., Torkhovskaya, T. I., Ipatova, O. M., & Archakov, A. I. (2018) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20186401066 · Cited by 1
Patanwala, R. M., Agarwal, M., Anand, S. P., Sawant, V. A., & Singla, R. (2019) · Clinical Lipidology and Metabolic Disorders · doi:10.1080/26415321.2019.1670555 · Cited by 2
“The marginally high triglyceride levels dropped after initiation of rosuvastatin and there is a possibility that the increase in HDL-C levels was owing to the welldocumented inverse relationship between the concentrations of TG and HDL-C[33].”
BackgroundInfluentialMolecular mechanisms of antiatherogenic drugs action
Lizunov, A. V., & Бычков, Э. Р. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf193291-301 · Cited by 1
Triple Fixed Antihypertensive and Lipid-Lowering Combination – Luxury or Intention?
Пристром, А. М. (2023) · Кардиология в Беларуси · doi:10.34883/pi.2023.15.4.013 · Cited by 2
Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs
Crook, M. (2011) · Annals of Clinical Biochemistry · doi:10.1258/acb.2010.010269 · Cited by 1
Hu, M., Mak, V. W. L., & Tomlinson, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011415411 · Cited by 1
Asiimwe, I. G., Jorgensen, A., & Pirmohamed, M. (2024) · medRxiv · doi:10.1101/2024.12.13.24318982 · Cited by 1
Asiimwe, I. G., Jorgensen, A., & Pirmohamed, M. (2024) · medRxiv · doi:10.1101/2024.12.13.24318985 · Cited by 1
Enhancing Fairness in Diabetes Prediction Systems through Smart User Interface DesignPreprint
Tavangar, A., Arefzadeh, Z., & Asghari, A. N. (2025) · medRxiv · doi:10.1101/2025.06.04.25328959 · Cited by 3
“…-tracked activity data[24]; dietary intake data [25]; fasting status [30] HDL exercise data[24]; dietary intake data [25]; medication use from EHRs [31] LDL metrics via wearables[24]; dietary intake data [25]; medication use from EHRs [31] Diabetes Pedigree Function Lifestyle data from patient…”
Humoral response towards high density lipoprotein : a new mechanism for atherogenesis
Batuca, J. R. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch11
Lu, Y. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Tsuji, S., Nohara, A., Hayashi, Y., Yoshida, I., Oka, R., Moriuchi, T., Hagishita, T., Miyamoto, S., Suzuki, A., Okada, T., et al. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.25825
Inhibidores de la protena transferidora de steres de colesterol. Cul es su futuro
Ros, E. (2010) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(10)70022-x
Role of HDL-C as a cardiovascular risk factor: clinical relevance of pitavastatin
Chapman, M. J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.23
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
LIPRIMAR®. FIFTEEN YEARS OF EVIDENCE
Susekov, A. V., & Хохлова, Н. В. (2011) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2011-7-2-231-240
“По результатам вторичного анализа базы данных VOYAGER (n=32 258), снижение уровня ХС ЛНП при лечении розувастатином 5-40 мг/сут было в диапазоне 39-55%, у больных, принимавших оригинальный аторвастатин 10-80 мг/сут, — 36-50% [37].”
From the NLA President: Making the right connections
Bittner, V. (2010)
The Genetics of Coronary Heart Disease across Ethnicities and in those with Type 2 Diabetes
Beaney, K. (2016) · Doctoral thesis, UCL (University College London). · Cited by 1
Statins and Cholesterol: A Perspective Revisited
Raina, V. (2018) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v6i4.203
“[27, 28] However, there is not enough evidence that sheds light on association of antiatherogenic properties of increasing HDL.”
BackgroundGaoming, Y. A. N. G., Han, D., Ma, J., & ZHANG, X. (2020) · Iranian Journal of Public Health · doi:10.18502/ijph.v48i8.2979
Leptin and cardiovascular health in high body mass index
Liew, C. H., Sim, W. H., Low, E. Z., & Chan, B. C. M. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02288-2
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type
Kim, J., Kim, H.-S., Yang, W., Lee, J., & Kang, H. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176309
“Most statins modestly raise the HDL-cholesterol level even though they mainly reduce the risk of CCVDs through HMG-CoA reductase inhibition and LDL-cholesterol-lowering mechanisms [15].”
BackgroundIs it possible to predict atherosclerosis in the ascending aorta by the patient’s lipid panel?
Haberal, İ., Yeşiltaş, M. A., Koyuncu, A. O., Batur, Ş., Özsoy, S. D., Ak, H. Y., & Buge, A. (2020) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2020.98940 · Cited by 1
“In fact, since rosuvastatin and simvastatin are thought to have the effect of increasing HDL-C, we also prefer these statins in our patient groups [23].”
BackgroundIs It Possible to Predict the Atherosclerosis in Aorta by the Patients Lipids Panel?Preprint
Yeşiltaş, M. A., Haberal, İ., Koyuncu, A. O., Batur, Ş., Özsoy, S. D., Ak, H. Y., & ÖZ, A. B. (2020) · doi:10.21203/rs.3.rs-29282/v1
business plan complexe de football indoor
Maxime, E. (2011) · Publications Docs-en-stock.com
Suciangto, W., Rasyid, H., Nasrum, N. I. R., & Rahmani, M. Z. (2021) · Nusantara Medical Science Journal · doi:10.20956/nmsj.v6i1.12243
“(21) (32) (33) (34) Moreover, statins can also prevent atherosclerotic plaque rupture that is common in COVID-19 patient with coronary heart disease.”
BackgroundIsrael, A., & Grossman, E. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.10.024
Lee, M., & Lee, B. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_7
Fundamentals of ophthalmic dispensing 20: Personal eye protection 1
Black, P., & Black, T. A. (2021) · Optician · doi:10.12968/opti.2021.8.8710
The Impact of Statin Dose, Class, and Intensity on Sepsis Mortality in Type 2 Diabetes PatientsPreprint
Sun, M., Tao, Y., Chen, W., Wu, S., & Zhang, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2892046/v1
Koutsogianni, A. D., Barkas, F., Tellis, C. C., Tselepis, A. D., Liamis, G. L., & Liberopoulos, E. N. (2023) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1051
Naseroleslami, M., & Mohseni, M. M. (2024) · ̒Ulūm va funūn-i bastah/bandī · doi:10.61186/ibj.3994 · Cited by 1
“J. 28 (1): 15-22 antifibrotic properties against cardiac I/RI, independent of its cholesterol-lowering role [7,8] .”
BackgroundLawton, R. I., Frankenberg, E., Seeman, T. E., Karlamangla, A. S., Sumantri, C. S., & Thomas, D. (2024) · National Bureau of Economic Research · doi:10.3386/w32489
Efektivitas Rosuvastatin Dan Pravastatin Sebagai Anti-Dislipidemia Pada Tikus JANTAN
Furqan, R. N., Nugraha, D. F., Hakim, A. R., Saputri, R., & Komaliya, R. (2024) · Journal Pharmaceutical Care and Sciences · doi:10.33859/jpcs.v4i2.485
Pharmacological Interventions of Metabolic Syndrome
Mehta, A. A., Beladiya, J., & Gandhi, T. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-75686-3_22 · Cited by 2
Machine Learning Approaches to Predict Alcohol Consumption from Biomarkers in the UK BiobankPreprint
Hassan, M. F., Gentry, A. E., Prom‐Wormley, E. C., Peterson, R. E., & Webb, B. T. (2024) · medRxiv · doi:10.1101/2024.12.22.24319486 · Cited by 2
Treatment of dyslipidemia: PCSK-9 in focus
Lukač, S. S., Popović, L., Rasulić, I., Petakov, A., Bogdanović, J. M., Mitrović, M., Krstic, M., & Lalic, K. S. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-55356
Baruah, J., Kalita, S., Kumar, P., Gupta, A., Lahon, D., & Sarmah, J. (2025) · Cureus · doi:10.7759/cureus.92213
“The higher HDL in our cases is less typical; modest HDL increases can occur with lipid‑modifying pharmacotherapy such as statins or fibrates, which may partially explain this signal in observational data [15, 16].”
Savinelli, S., Heeney, A., Tinago, W., Leon, A. A. G., McGettrick, P., Cotter, A. G., Walsh, I., Fitzgibbon, M. C., Sabin, C. A., Mallon, P. W. G., et al. (2025) · HIV Medicine · doi:10.1111/hiv.70118 · Cited by 3
“While statins are highly effective in lowering LDL levels, their effects on HDL are variable and independent from LDL decrease, with some patients experiencing an increase in the levels of HDL, while others experience a paradoxical decrease in HDL [46].”
Ghaemi, F., Hedayati, F., Esteghamati, A., Peysepar, R., Deravi, N., & Meysamie, A. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02050-8 · Cited by 1
“The decrease in impaired HDL levels may be partly attributable to the widespread prescription of statins among patients with diabetes [37].”
Metabolomics of aortic valve stenosis: Are aortic valve stenosis and sclerosis different diseases?
Koljonen, E., Kärkkäinen, O. K., Haikonen, R., Turpeinen, A., Hartikainen, J. E. K., & Rysä, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120549
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Tegg, M. (2014) · Research Online (Edith Cowan University) · doi:10.13140/rg.2.1.1360.2807 · Cited by 1
Additional file 1 of Optimal statin use for prevention of sepsis in type 2 diabetes mellitus
Sun, M., Tao, Y., Chen, W.-M., Wu, S.-Y., & Zhang, J. (2023) · Figshare · doi:10.6084/m9.figshare.22655279
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 2
“Statins reduce LDL-C up to about 50% depending on the drug and the dose, and they are also associated with smaller reductions in triglycerides, which are greater with higher baseline triglyceride levels, and usually a small and variable increase in HDL-C [40,41].”
Challenges in achieving low-density lipoprotein targets: a cross-sectional study in statin users
Çiçekli, A., & Sağlan, Y. (2026) · Turkish Journal of Family Practice · doi:10.54308/turkjfampract.2026.888 · Cited by 1
“[11] In the treatment of dyslipidemia, the target lipid levels are determined based on cardiovascular risk stratification.”
Taheri, E., Esmaeili, S., Hamidizadeh, S., Seighali, N., Mehrpour, A., Beiky, M., Javazm, A. K., Soltani, H., Ahmadi, A., Basirat, E., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120725
Sharma, P. K., Gupta, A., Singh, V., Midha, N. K., & Kumar, B. (2026) · Journal of Primary Care Specialties · doi:10.4103/jopcs.jopcs_2_26
Gnanapradeepan, K., Manska, S., Schwartz, B., Golczer, G., Huang, J., Kelkar, R. S., Masteller, A. M., Pilankar, S., Richter, M., Waldron, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729508
Statins and insulin resistance
Djabir, Y. Y., & Arsyad, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00001-4
Thandi, P., Pradhan, A. K., Agarwala, R., Puri, R., & Perrone, M. A. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.88
Lipid lowering efficacy and safety of atorvastatin and rosuvastatin
Arshad, A. R. (2020) · Harvard Dataverse · doi:10.7910/dvn/u8nlqc
Metadata
- Authors
- Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J.
- Affiliations
- The Heart Research Institute (AU)
- Keele University (GB)
- Cleveland Clinic (US)
- Corresponding author
- Barter, Philip J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 51
- Issue
- 6
- Pages
- 1546-1553
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC3035518
- OpenAlex
- W2134105637
- Cited by
- 259
- References
- 38
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 11 · 2021: 19 · 2020: 17 · 2019: 8 · 2018: 16 · 2017: 11 · 2016: 15 · 2015: 15 · 2014: 23 · 2013: 15 · 2012: 13
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3790 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, HDL cholesterol, LDL cholesterol, rosuvastatin, atorvastatin, simvastatin, apolipoprotein A-I, triglycerides, diabetes mellitus, dyslipidemia, statin dose
- MeSH terms
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.